Beximco Pharmaceuticals Limited (BST:R2WA)

Market Cap	329.43M
Revenue (ttm)	373.79M
Net Income (ttm)	51.25M
Shares Out	n/a
EPS (ttm)	0.11
PE Ratio	6.43
Forward PE	7.53
Dividend	0.02 (5.91%)
Ex-Dividend Date	Nov 22, 2024

Volume	n/a
Average Volume	1,460
Open	0.4280
Previous Close	0.4220
Day's Range	0.4220 - 0.4280
52-Week Range	0.2260 - 0.4820
Beta	n/a
RSI	52.92
Earnings Date	Nov 3, 2025

About Beximco Pharmaceuticals

Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh. The company provides allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskeletal, oncology, respiratory, urogenital, skin care, vitamin and mineral supplement, and other products, as well as contract manufacturing services to ...

• Industry: Pharmaceutical Preparations
• Founded: 1976
• Employees: 1,122
• Stock Exchange: Stuttgart Stock Exchange
• Ticker Symbol: R2WA

Financial Performance

In 2024, Beximco Pharmaceuticals's revenue was 44.39 billion, an increase of 13.05% compared to the previous year's 39.27 billion. Earnings were 5.83 billion, an increase of 26.34%.

Financial numbers in BDT